|
Macharadze D.Sh.
New treatment options for severe atopic dermatitis: upadacitinib. Review
|
№7 / 2025
|
|
L.L. Rusakova, N.N. Murashkin
Dynamics of laboratory blood parameters in children with atopic dermatitis who received biological therapy with AN IL-4, IL-13 inhibitor in combination with topical therapy methods
|
№1 / 2025
|
|
Rusakova L.L., Murashkin N.N.
Evaluation of the efficacy and safety of combination therapy and prevention of exacerbations of atopic dermatitis in children with moderate and severe forms of the disease
|
№10 / 2024
|
|
Rusakova L.L., Murashkin N.N.
Evaluation of atopic dermatitis severity indices in patients receiving IL-4, IL-13 inhibitor therapy (dupilumab) in combination with topical treatment methods
|
№10 / 2024
|
|
Sokolovsky E.V., Kholodilova N.A., Monakhov K.N.
Atopic dermatitis: current treatment options
|
№6 / 2024
|
|
A.M. Dogov, N.N. Murashkin, E.T. Ambarchyan
Efficacy of dupilumab in children with alopecia areata and atopic dermatitis
|
№13 / 2023
|
|
O.A. Bashkina, I.V. Vyazovaya, D.F. Sergienko
Difficult patient with bronchial asthma: a clinical case
|
№10 / 2022
|
|
D.F. Sergienko
Targeted therapy with dupilumab for children in the Astrakhan region: a clinical study
|
№9 / 2022
|
|
A.S. Botkina, M.I. Dubrovskaya, O.O. Khandamirova
Targeted therapy of atopic dermatitis in children
|
№8 / 2022
|
|
Yu.P. Moiseeva, G.Z. Piskunov, S.Ya. Kosyakov, A.A. Kirsanova, E.F. Shaikhutdinova
New options for the treatment of patients with uncontrolled course of chronic rhinosinusitis with nasal polyps with dupilumab: a clinical case
|
№5 / 2022
|
Русский
